A large body of genomic data appear to confirm emerging safety data from anti-IL-13/IL-4 clinical use that prolonged blocking of IL-13 is not associated with reduced systemic immunity or opportunistic infections. The gene discussed is IL4; the disease is Opportunistic infection.